Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kindred Biosciences (KIN)

Kindred Biosciences (KIN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,696
  • Shares Outstanding, K 39,492
  • Annual Sales, $ 4,260 K
  • Annual Income, $ -61,390 K
  • 60-Month Beta 1.19
  • Price/Sales 4.53
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade KIN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.33
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.08 +20.83%
on 12/31/20
5.21 -5.37%
on 01/08/21
+0.25 (+5.34%)
since 12/22/20
3-Month
3.46 +42.49%
on 11/02/20
5.21 -5.37%
on 01/08/21
+0.80 (+19.37%)
since 10/22/20
52-Week
3.11 +58.78%
on 03/23/20
11.93 -58.68%
on 02/28/20
-4.95 (-50.10%)
since 01/22/20

Most Recent Stories

More News
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study...

KIN : 4.93 (+10.79%)
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFa Antibody for Canine Inflammatory Bowel Disease

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness...

KIN : 4.93 (+10.79%)
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting  exclusive global rights...

KIN : 4.93 (+10.79%)
ELAN : 30.46 (+0.23%)
Elanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to Market

Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody...

KIN : 4.93 (+10.79%)
ELAN : 30.46 (+0.23%)
Worldwide Veterinary Medicines Industry to 2028 - by Animal Type, Distribution Channel, Route of Administration and Product

, /PRNewswire/ -- The report has been added to offering.

DCHPF : 45.5000 (unch)
EVKIY : 16.3200 (-2.10%)
KIN : 4.93 (+10.79%)
MRK : 80.98 (-0.25%)
NEOG : 86.17 (+3.12%)
VRBCF : 271.0000 (unch)
Kindred Biosciences to Present at Guggenheim Animal Health Summit

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. , Chief Executive Officer, will present...

KIN : 4.93 (+10.79%)
Kindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare Symposium

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel Virtual Healthcare Conference on ...

KIN : 4.93 (+10.79%)
Kindred Biosciences (KIN) Reports Q3 Loss, Tops Revenue Estimates

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

KIN : 4.93 (+10.79%)
Kindred Bio: 3Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Monday reported a loss of $12.2 million in its third quarter.

KIN : 4.93 (+10.79%)
Kindred Biosciences Announces Third Quarter 2020 Financial Results

, /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended...

KIN : 4.93 (+10.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have...

See More

Key Turning Points

3rd Resistance Point 5.80
2nd Resistance Point 5.38
1st Resistance Point 5.16
Last Price 4.93
1st Support Level 4.52
2nd Support Level 4.10
3rd Support Level 3.88

See More

52-Week High 11.93
Fibonacci 61.8% 8.56
Fibonacci 50% 7.52
Fibonacci 38.2% 6.48
Last Price 4.93
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar